Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Don't Let Fear of Cancer Keep You From Doctor VisitsMaker Halts Distribution of Generic Zantac Due to Possible CarcinogenCould Profit Be a Factor in Kidney Transplant Decisions?Get Up-to-the-Minute Safety Alerts Sent Straight to Your InboxPurdue Pharma to Settle Opioid Crisis Lawsuits, May Pay Up to $12 BillionWould a Health Warning on Every Cigarette Help Smokers Quit?Docs Prescribe More Opioids at Certain Time of DayFDA Warns Juul About Illegal Marketing Claims and Pitch to YouthComing Soon: A 'Pot Breathalyzer'?More CT, MRI Scans Being Used, Despite Calls to Cut BackCancer Overtakes Heart Disease as #1 Killer of Middle-Aged in Wealthy NationsOxyContin Maker Purdue Offering Up to $12 Billion to Settle Opioid ClaimsThousands of Kidneys Thrown Away by U.S. Transplant CentersJudge Orders Johnson & Johnson to Pay $572 Million Over Opioid Drug CrisisEvery Sudden Infant Death Deserves a Closer Look: ReportYour Chocolate Pot 'Edible' Could Hold a Hidden DangerCBD Is the Rage, But More Science Needed on Safety, EffectivenessMany Parents Would Switch Doctors Over Vaccination Policy, Poll FindsPot Poisonings Among Kids, Teens Double After Medical Marijuana Law PassedNearly Half of U.S. Patients Keep Vital Secrets From Their DoctorsFDA Proposes Graphic Warning Labels on CigarettesMany Doctors Refusing Care of People Prescribed OpioidsAll U.S. Adults Should Be Screened for Illicit Drug Use, National Panel UrgesAmericans' Trust in Scientists Follows a Sharp Political DivideRaising Legal Smoking Age to 21 WorksPure CBD Won't Make You Fail a Drug Test, But…Health Tip: Donate Blood SafelyRoutine Screening for Pancreatic Cancer Not Warranted, Expert Panel SaysResearchers 'Spin' Clinical Trial Findings in Top Psych Journals: StudyMore 'Buyer Beware' Warnings for Unregulated Stem Cell ClinicsSome of Most Common, Deadly Cancers Get the Least Research MoneyTraveling Abroad? Make Sure Your Measles Shot Is Up to DateHey! That's the Wrong Knee, DoctorBlood Donations Needed: Red CrossKeep Unused Meds Out of the Hands of AddictsFew U.S. Universities Are Smoke-FreeNeed Emergency Air Lift to Hospital? It Could Cost You $40,000California Took on Anti-Vaxxers, and WonAnti-Vaccine Movement a 'Man-Made' Health Crisis, Scientists WarnAHA News: Even the Threat of Homelessness May Bring Higher Stroke RiskFDA Warns Two Kratom Marketers About False ClaimsExperts Want Doctors to Add Vaping to Youth Prevention PitchMany Health Care Workers With Flu, Colds Still Go to Work: StudyGlobal Efforts to Cut Smoking Show Mixed ResultsOne Simple Food Substitution Might Help Save the PlanetAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideRace Affects Life Expectancy in Major U.S. CitiesDrugstores Often Don't Have Opioid Antidote in Stock, Philly Study ShowsAntibiotics Pollute Rivers Worldwide: StudyAHA News: For LGBTQ Patients, Discrimination Can Become Barrier to Medical Care
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

FDA Warns Two Kratom Marketers About False Claims

HealthDay News
by -- Robert Preidt
Updated: Jun 25th 2019

new article illustration

TUESDAY, June 25, 2019 (HealthDay News) -- The U.S. Food and Drug Administration on Tuesday took two kratom marketers to task over false claims that their products can treat or cure opioid addiction.

The latest salvo is part of the agency's continuing efforts to alert consumers about the potential dangers of the herbal drug.

The warning letters were sent to Cali Botanicals of Folsom, Calif., and Kratom NC of Wilmington, N.C., for illegally selling unapproved, misbranded kratom-containing drug products with unproven claims about their ability to treat or cure opioid addiction and withdrawal symptoms.

The companies also make unproven claims that the products treat pain and other medical conditions such as depression, anxiety and cancer.

The companies were given 15 working days to outline what actions they'll take to address the FDA's concerns. Failure to act may result in product seizures or injunctions.

"We have issued numerous warnings about the serious risks associated with the use of kratom, including warnings about the contamination of kratom products with high rates of salmonella that put people using kratom products at risk, and resulted in numerous illnesses and recalls," Acting FDA Commissioner Dr. Ned Sharpless said in an agency news release.

"As part of our efforts to assess kratom for contamination in the products tested, we also found high levels of heavy metals in kratom products. Despite our warnings, companies continue to sell this dangerous product and make deceptive medical claims that are not backed by science or any reliable scientific evidence," Sharpless added.

"As we work to combat the opioid crisis, we cannot allow unscrupulous vendors to take advantage of consumers by selling products with unsubstantiated claims that they can treat opioid addiction or alleviate other medical conditions," he said.

Kratom (Mitragyna speciosa), a plant that grows naturally in Thailand, Malaysia, Indonesia and Papua New Guinea, is not legally marketed in the United States as a drug or dietary supplement. There are no FDA-approved uses for kratom, and the agency said it has received reports about dangers posed by kratom.

Data suggest that certain substances in kratom have opioid properties that put users at risk of addiction, abuse and dependence, according to the FDA.

A U.S. Centers for Disease Control and Prevention study published in April found that over an 18-month period (July 2016 through December 2017), kratom was a contributing factor in 91 drug overdose deaths.

In seven of those cases, kratom was the only drug detected in postmortem testing, according to the study that examined data from 27 states.

Along with those 91 deaths in which kratom was at least a contributing factor, 61 other people who suffered fatal drug overdoses were found to have kratom in their bloodstreams, although other drugs may have caused the deaths, the CDC researchers said at the time.

The FDA warns consumers not to use any products labeled as containing the botanical substance kratom or its psychoactive compounds, mitragynine and 7-hydroxymitragynine.

The U.S. Drug Enforcement Agency has also listed kratom as a "drug of concern."

More information

The U.S. Food and Drug Administration has more on kratom.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net